APSR2026-502

 
Late-Breaking
Submitted
Poster Presentation
 
AP05-004
P107
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1276180-46904-APSR 05004 Taverner_440560.pdf
Format: PDF Only
12. Bronchoscopy and Interventional Techniques
6

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

John Taverner * Alfred Health Lung Transplant Service Melbourne Australia
Nicole Gaffney - Alfred Health Lung Transplant Service Melbourne Australia
Sakhee Kotecha - Alfred Health Lung Transplant Service Melbourne Australia
Miranda Paraskeva - Alfred Health Lung Transplant Service Melbourne Australia
Glen Westall - Alfred Health Lung Transplant Service Melbourne Australia
Gregory Snell - Alfred Health Lung Transplant Service Melbourne Australia
 
 
 
 
 
 
 
 
 
Presenting Author Details
John
Taverner
john.taverner@alfred.org.au
+61412400093
31-40
Australia
Original Research
Transbronchial lung biopsy in lung transplant recipients: 20 years of progress?
Maximum 25 words
Abstract Content
Transbronchial lung biopsy (TBB) is the gold standard tool for histopathological diagnosis of acute rejection (AR) in lung transplant recipients undergoing surveillance bronchoscopy (SB) or bronchoscopy for clinical indication (CB). We evaluated the performance of TBB at a high-volume lung transplant centre and compared to those published from the same centre in 2003.
SB with TBB and bronchoalveolar lavage (BAL) is performed at weeks 2 and 6 and months 3, 6 and 12 post-transplant under sedation with fluoroscopic guidance. Airway complications are graded according to ISHLT guidelines. Sufficient biopsies are performed to provide 5-6 pieces of lung parenchyma. All bronchoscopies with TBB transplant recipients over 12 months were reviewed. Proportions were compared with Pearson’s chi-squared test and P value <0.05 determined statistical significance.
235 bronchoscopies were performed on 124 patients (206 SB and 29 CB). Time post transplant: 109 cases <3 months, 78 cases 3-12 months and 35 cases >12 months. TBB was adequate for analysis in 88.1%, limited in 7.7% and insufficient in 4.3%. Mean fragments provided was 4 (SD +/-1) and 28.9% met ISHLT critera for specimen adequacy. AR grade A2 was diagnosed in 2 cases (1.0%) and AR grade 1 in 4 cases (1.9%), all <12 months post transplant. AR rates were not correlated to bronchoscopy indication (P=0.762) or ISHLT specimen adequacy (P=0.258). Airway complications occurred in 28 cases (20.9%) and significant infections in 40 cases (17%), most commonly fungal. There were 7 pneumothoracies (3.0%) with one case requiring ICC (0.4%) and one case of severe bleeding (0.4%). Compared to previously published results, there has been a significant reduction in the rate of AR (A2 or greater) (P<0.001, 95% CI 0.00-0.02) but no change in the rate of clinically significant infections (P=0.1).
In our centre the rate of AR has declined significantly over time. This may be due to improved immunosuppression regimes although specimen quality may contribute. Whilst bronchoscopy detects significant infections and airway complications, the benefit of TBB needs to be reassessed.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
Lung transplant, bronchoscopy, transbronchial biopsy
maximum 3 keywords and no abbreviations, separated by commas
 
347